

**Amendments to the Claims:**

1. **(Currently amended):** A chicken astrovirus type 2 (CAstV-2), characterised in that the virus is the CAstV deposited under accession no. I-2932 at the Collection Nationale de Cultures de Microorganismes (CNCM) of the Institute Pasteur, Paris, France or a CAstV-2 that is able to induce antiserum having a neutralizing antibody titre greater than or equal to 128 against the deposited virus as measured in a virus neutralization assay[[-]]  
**and greater than or equal to 32 as measured in an immunofluorescence assay.**

Claims 2 – 3 (Canceled)

4. **(Previously presented):** An immunogenic composition comprising a CAstV-2 according to claim 1, together with a pharmaceutically acceptable carrier or diluent.
5. **(Previously presented):** The immunogenic composition according to claim 4, characterized in the CAstV-2 is in a live attenuated form.
6. **(Previously presented):** The immunogenic composition of claim 4, further comprising one or more vaccine components of other pathogens infectious to poultry.
7. **(Previously presented):** The immunogenic composition according to claim 4, further comprising an adjuvant.

USSN: 10/527,767

Attorney Docket: 2002.016 US

Response to Office Action of August 6, 2008

8. (Previously presented): A method for the preparation of CAstV-2 antigen material, wherein a CAstV-2 according to claim 1 is propagated in a cell culture and subsequently harvested from the cell culture.

**[[8.]] 9.** (Currently amended): A method for the preparation of a vaccine according to claim 4, an immunogenic composition, wherein a CAstV-2 according to claim 1 is mixed with a pharmaceutical pharmaceutically acceptable carrier or a diluent.

**[[9.]] 10.** (Currently amended): A method for raising an immune response in poultry, against avian astrovirus, comprising administering an immunogenic composition according to claim 4 to poultry.